Gary Panik, DO
Family Medicine · New Tripoli, PANPI 1073509998
Payments from drug & device makers
Across 314 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$987
- Boehringer Ingelheim$724
- AstraZeneca$655
- Lilly USA, LLC$438
- Johnson & Johnson$392
- Pfizer$347
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,982100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 64 | $987 |
| Boehringer Ingelheim | 36 | $724 |
| AstraZeneca | 40 | $655 |
| Lilly USA, LLC | 34 | $438 |
| Johnson & Johnson | 24 | $392 |
| Pfizer | 31 | $347 |
| GSK | 20 | $323 |
| Merck | 16 | $246 |
| AbbVie(2 entities) | 7 | $140 |
| Esperion Therapeutics, Inc. | 9 | $139 |
| Biohaven Pharmaceuticals, Inc. | 7 | $117 |
| Eisai Inc. | 2 | $80 |
| Sanofi-aventis U.S. LLC | 5 | $75 |
| Amgen | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Seqirus USA Inc | 2 | $28 |
| Phadia US Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Abbott | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Mannkind Corporation | 1 | $20 |
| Bayer | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,990 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 71 | $92,064 |
| TrulicityDulaglutide | 66 | $77,340 |
| EliquisApixaban | 55 | $69,480 |
| XareltoRivaroxaban | 42 | $46,761 |
| JanuviaSitagliptin Phosphate | 34 | $44,063 |
| FarxigaDapagliflozin Propanediol | 32 | $40,018 |
| OzempicSemaglutide | 14 | $23,888 |
| MounjaroTirzepatide | 17 | $17,096 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $16,070 |
| Metoprolol Succinate | 141 | $3,046 |
| Atorvastatin Calcium | 255 | $2,649 |
| Rosuvastatin Calcium | 140 | $2,303 |
| Levothyroxine Sodium | 216 | $2,125 |
| Losartan Potassium | 196 | $1,980 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $1,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $438 | $94,43683 claims |
| Boehringer IngelheimJardiance | $724 | $92,06471 claims |
| PfizerEliquis | $347 | $69,48055 claims |
| Johnson & JohnsonXarelto | $392 | $46,76142 claims |
| MerckJanuvia | $246 | $44,06334 claims |
| AstraZenecaFarxiga | $655 | $40,01832 claims |
| Novo NordiskOzempic | $987 | $23,88814 claims |
| GSKTrelegy Ellipta | $323 | $16,07013 claims |
| AbbVieSynthroid | $140 | $1,34830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in New Tripoli
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.